Clinical Presentation
The indications for reoperation were aortic regurgitation in 75 patients (52.1%), aortic stenosis in 28 (19.4%), and mixed aortic valve disease in 41 (28.5%) [PMID:10567277].
Management
From the FRANCE registry, the mean hospital stay cost was significantly influenced by the procedural site, being lowest in the catheterization laboratory [PMID:23706367].
Early mortality was 3.4%, with actuarial survival rates of 93% at 5 years and 82% at 10 years [PMID:10567277].
Complications
Multivariable analysis in the FRANCE registry identified complications during the procedure and subsequent pacemaker implantation as factors significantly associated with increased hospital stay costs [PMID:23706367].
Prognosis & Follow-up
Higher hospital stay costs were observed in patients with a Society of Thoracic Surgeons score greater than 10%, indicating potential resource intensity for high-risk patients [PMID:23706367].
Freedom from tissue degeneration was 96% and 80% at 5 and 10 years, respectively, and freedom from reoperation was 97% and 82% at 5 and 10 years, respectively [PMID:10567277].
References
1 Chevreul K, Brunn M, Cadier B, Haour G, Eltchaninoff H, Prat A et al.. Cost of transcatheter aortic valve implantation and factors associated with higher hospital stay cost in patients of the FRANCE (FRench Aortic National CoreValve and Edwards) registry. Archives of cardiovascular diseases 2013. link 2 Hasnat K, Birks EJ, Liddicoat J, Hon JK, Edwards S, Glennon S et al.. Patient outcome and valve performance following a second aortic valve homograft replacement. Circulation 1999. link
2 papers cited of 3 indexed.